Applied StemCell Launches hiEX™ Research iPSC Exosomes to Power Next-Generation Regenerative Medicine Research

Applied StemCell, a leading provider of advanced stem cell and gene editing technologies since 2008, today announced the release of hiEX™ Research iPSC Exosomes, a new research-use-only product designed to enable scientists to explore the therapeutic potential of iPSC-derived exosomes in areas such as wound healing, aging, and nerve regeneration.

Isolated from a single, well-characterized induced pluripotent stem cell (iPSC) line, hiEX™ Research iPSC Exosomes offer a consistent and scalable alternative to donor-derived exosomes. While available off-the-shelf in PBS, they can be custom-formulated and even engineered, thanks to the presence of Applied StemCell’s patented TARGATT™ large knock-in technology in the source cell line, turning hiEX™ Research iPSC Exosomes into a versatile platform for discovery and translational research.

“Exosomes offer exciting possibilities as cell-free tools in regenerative medicine,” said Dr. Ruby Tsai, CEO of Applied StemCell. “Our hiEX™ iPSC Exosomes give researchers a dependable and well-defined starting point for exploring those possibilities.”

By combining the scalability of iPSCs with rigorous quality control and the potential for fast gene knock-in into the parent line, hiEX™ Research iPSC Exosomes enable researchers to pursue deeper insights into regenerative mechanisms and lay the groundwork for therapeutic innovations.

For more information, visit the product page: https://appliedstemcell.com/product/hiex-research-ipsc-exosomes/

Source – Globe Newswire